Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000467997 | SCV000551358 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 4 | 2017-03-22 | criteria provided, single submitter | clinical testing | In summary, this variant is a rare frameshift variant that is expected to disrupt an important functional domain of the RAD51D protein. This evidence indicates that the variant is pathogenic, but additional data is needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This frameshift is expected to partially disrupt the C-terminus of the ATPase domain of the RAD51D protein (PMID: 14704354, 19327148, 21111057), which is required for interacting with RAD51C to assist DNA repair activity (PMID: 14704354, 19327148). While functional studies have not been reported for this particular variant, a truncating variant in the C- terminal region was found to segregate in three family members with ovarian cancer and family history of ovarian and breast cancers (Invitae database), suggesting that disruption of this region of the RAD51D protein is causative of disease. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a RAD51D-related disease. This sequence change inserts 1 nucleotide in exon 8 of the RAD51D mRNA (c.728dupT), causing a frameshift at codon 243. This creates a premature translational stop signal in the last exon of the RAD51D mRNA (p.Met243Ilefs*84). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 86 amino acids of the RAD51D protein. |